ESGE Days 2026, Endoscopy Journal Supplement As part of our mission in Milan to Reimagine Endoscopy : Smarter, together, and for the future we invite you to browse the research showcased in this publication
All medications come from licensed 503A compounding pharmacies, require no insurance or membership, and are HSA/FSA eligible
This figure is remarkable in the context of GLP-1 therapeutics: oral semaglutide (Rybelsus), despite incorporating the SNAC absorption enhancer, achieves oral bioavailability of only 0.4-1.0%, meaning that more than 99% of the ingested semaglutide peptide is lost to gastrointestinal degradation and poor absorption
"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis"
Average Results When paired with a proper nutrition and exercise program, patients on average are losing 5% 10% of their body weight after 12 weeks